Patterns of SARS-CoV-2-specific humoral and cellular immune response in actively treated patients with solid cancer following prime BNT162b2 COVID-19 vaccination: results from phase IV CoVigi trial.

Ther Adv Med Oncol · 2025 · PMC12085753 · PMID 40386467

Europe PMC DOI

hedged sentence

0.0920

closest p · 1.8× alpha

0.0920

boldest claim

The sentences

at the margin of statistical significancep = 0.092so close (0.05 < p ≤ 0.1)

Surprisingly, after the second dose of vaccine (V3), higher SARS-CoV-2-specific T-cell response levels were observed in SARS-CoV-2-naïve subjects with solid cancer at the margin of statistical significance ( p = 0.092) ( Table 3 ).

also in 77 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.